Preliminary ReportEffects of L-Thyroxine Therapy on Circulating Leptin and Adiponectin Levels in Subclinical Hypothyroidism: A Prospective Study
Introduction
Subclinical hypothyroidism (SCH) is defined as a serum thyroid-stimulating hormone (TSH) level above the upper limit of normal despite normal levels of serum free thyroxine (1). Although studies have demonstrated some adverse effects of SCH, there is neither a consensus regarding the clinical importance of the adverse effects nor the benefits of L-thyroxine therapy especially for patients with TSH levels <10 mIU/mL (1).
Adipose tissue is a hormonally active system that produces and releases different bioactive substances. Adiponectin and leptin are two of the adipokines released from adipose tissue and modulate homeostasis, lipid and glucose metabolism. Plasma adiponectin levels are correlated negatively with adiposity, insulin resistance, type 2 diabetes and metabolic syndrome. Leptin serves as a major ‘adipostat’ by repressing food intake and promoting energy expenditure. Independent of these, leptin improves peripheral insulin sensitivity and modulates pancreatic β-cell function (2).
Hypothyroidism appears to be associated with alterations in the function of adipose tissue. Controversial data are available regarding changes in circulating adipokine levels in hypothyroid patients. Studies conducted in patients mainly with overt hypothyroidism due to various causes reported low, normal or high circulating leptin levels, whereas circulating adiponectin levels were unaltered in the majority of the studies (3). Similar discordant results have been reported with normalization of hypothyroidism by L-thyroxine treatment in that leptin levels either increased 4, 5, 6, unaltered 7, 8 or decreased 9, 10, whereas adiponectin levels did not show a significant change (11).
It is not clear whether adipose tissue function and secretion of adiponectin and leptin are altered in SCH. The aim of the current study was to determine levels of adiponectin and leptin in women with SCH and potential effects of L-thyroxine therapy on those levels.
Section snippets
Subjects
Forty three regularly menstruating premenopausal women with SCH and 53 age- and BMI-matched healthy control women were included. All participants were >18 years of age with normal body weight. SCH was defined as a TSH level >4.5 mIU/L associated with normal free thyroxine (fT4) (normal range: 12–22 pmol/l) and free triiodothyronine (fT3) (normal range 3.1–6.8 pmol/L) levels. Patients with a history of radioiodine exposure or thyroid surgery were excluded. Other exclusion criteria were
Results
Clinical, hormonal and metabolic characteristics of the patients and controls are shown in Table 1. Patients with SCH had higher TSH (p <0.001) and lower fT4 levels (p <0.001) than controls at baseline. The two groups had similar values for other clinical and laboratory parameters (Table 1). Leptin and adiponectin did not correlate with TSH or free thyroid hormones in patients and controls using Spearman’s correlation.
All patients with SCH reached euthyroid status after 6 months of L-thyroxine
Discussion
We report here that premenopausal women with SCH have similar adiponectin and leptin levels in comparison with age- and BMI-matched healthy women. Achievement of euthyroid status by replacement therapy increases adiponectin and decreases leptin levels. These alterations do not appear to be accompanied by any change in body fat amount or distribution.
Studies comparing hypothyroid patients with euthyroid controls have reported normal, decreased or increased serum leptin levels (11). Leptin
References (23)
- et al.
Influence of thyroid dysfunction on serum concentrations of adipocytokines
Cytokine
(2007) - et al.
Unchanged serum adipokine concentrations in the setting of short-term thyroidectomy-induced hypothyroidism
Endocr Pract
(2012) - et al.
T3 and Triac inhibit leptin secretion and expression in brown and white rat adipocytes
Biochim Biophys Acta
(2004) - et al.
Circulating adiponectin concentrations were related to free thyroxine levels in thyroid cancer patients after thyroid hormone withdrawal
Metabolism
(2010) Clinical practice. Subclinical hypothyroidism
N Engl J Med
(2001)- et al.
Adipokines and insulin resistance
Mol Med
(2008) - et al.
Lack of effects of circulating thyroid hormone levels on serum leptin concentrations
Eur J Endocrinol
(1997) - et al.
Influence of thyroid status on serum immunoreactive leptin levels
J Clin Endocrinol Metab
(1997) - et al.
Increased adipose tissue secretion of interleukin-6, but not of leptin, plasminogen activator inhibitor-1 or tumour necrosis factor alpha, in Graves’ hyperthyroidism
Eur J Endocrinol
(2002) - et al.
The effects of thyroid status on plasma leptin levels in women
J Endocrinol Invest
(1998)
Serum leptin and lipids in patients with thyroid dysfunction
J Atheroscler Thromb
Cited by (13)
Thyroid-Stimulating Hormone: Physiology and Secretion
2015, Endocrinology: Adult and PediatricNon-genomic actions of thyroid hormones: Molecular aspects
2014, Archives of Cardiovascular DiseasesCitation Excerpt :Leptin has a role in the regulation of thyrotropin-releasing hormone gene expression and thyroid-stimulating hormone directly stimulates leptin secretion by human adipose tissue. The relationship between adiponectin and thyroid hormones is not clearly defined [21]. Leptin has an NO-mediated vasodilative action, which is associated with blood pressure reduction.
Obesity, Adipokines and Thyroid Dysfunction
2021, Thyroid, Obesity and Metabolism: Exploring Links Between Thyroid Function, Obesity, Metabolism and LifestyleAdipocytokines and thyreopathies
2020, Vnitrni LekarstviTHE ROLE OF ADIPOKINES : LEPTIN, RESISTIN AND CRP IN THYROID DYSFUNCTION
2019, Biochemical and Cellular Archives